27270538|t|Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml
27270538|a|The European Society of Urogenital Radiology has built the Prostate Imaging Reporting and Data System (PI-RADS) for standardizing the diagnosis of prostate cancer (PCa). This study evaluated the PI-RADS diagnosis method in patients with prostate-specific antigen (PSA) <20 ng/ml. A total of 133 patients with PSA <20 ng/ml were prospectively recruited. T2-weighted (T2WI) and diffusion-weighted (DWI) magnetic resonance images of the prostate were acquired before a 12-core transrectal prostate biopsy. Each patient's peripheral zone was divided into six regions on the images; each region corresponded to two of the 12 biopsy cores. T2WI, DWI, and T2WI + DWI scores were computed according to PI-RADS. The diagnostic accuracy of the PI-RADS score was evaluated using histopathology of prostate biopsies as the reference standard. PCa was histologically diagnosed in 169 (21.2%) regions. Increased PI-RADS score correlated positively with increased cancer detection rate. The cancer detection rate for scores 1 to 5 was 2.8%, 15.0%, 34.6%, 52.6%, and 88.9%, respectively, using T2WI and 12.0%, 20.2%, 48.0%, 85.7%, and 93.3%, respectively, using DWI. For T2WI + DWI, the cancer detection rate was 1.5% (score 2), 13.5% (scores 3-4), 41.3% (scores 5-6), 75.9% (scores 7-8), and 92.3% (scores 9-10). The area under the curve for cancer detection was 0.700 (T2WI), 0.735 (DWI) and 0.749 (T2WI + DWI). The sensitivity and specificity were 53.8% and 89.2%, respectively, when using scores 5-6 as the cutoff value for T2WI + DWI. The PI-RADS score correlates with the PCa detection rate in patients with PSA <20 ng/ml. The summed score of T2WI + DWI has the highest accuracy in detection of PCa. However, the sensitivity should be further improved.
27270538	18	60	Prostate Imaging Reporting and Data System	T170	C4284879
27270538	65	91	Magnetic Resonance Imaging	T060	C0024485
27270538	92	101	Diagnosis	T062	C1704656
27270538	105	120	Prostate Cancer	T191	C0376358
27270538	124	132	Patients	T101	C0030705
27270538	138	163	Prostate-specific Antigen	T116,T126,T129	C0138741
27270538	178	218	European Society of Urogenital Radiology	T093	C1708333
27270538	233	275	Prostate Imaging Reporting and Data System	T170	C4284879
27270538	277	284	PI-RADS	T170	C4284879
27270538	308	317	diagnosis	T062	C1704656
27270538	321	336	prostate cancer	T191	C0376358
27270538	338	341	PCa	T191	C0376358
27270538	349	354	study	T062	C2603343
27270538	369	376	PI-RADS	T170	C4284879
27270538	377	393	diagnosis method	T060	C0430022
27270538	397	405	patients	T101	C0030705
27270538	411	436	prostate-specific antigen	T116,T126,T129	C0138741
27270538	438	441	PSA	T116,T126,T129	C0138741
27270538	469	477	patients	T101	C0030705
27270538	483	486	PSA	T116,T126,T129	C0138741
27270538	527	538	T2-weighted	T060	C0011923
27270538	540	544	T2WI	T060	C0011923
27270538	550	600	diffusion-weighted (DWI) magnetic resonance images	T060	C0598801
27270538	608	616	prostate	T023	C0033572
27270538	640	675	12-core transrectal prostate biopsy	T060	C0401641
27270538	682	691	patient's	T101	C0030705
27270538	692	707	peripheral zone	T029	C0458696
27270538	744	750	images	T170	C1704254
27270538	794	806	biopsy cores	T060	C3846093
27270538	808	812	T2WI	T060	C0011923
27270538	814	817	DWI	T060	C0598801
27270538	823	827	T2WI	T060	C0011923
27270538	830	833	DWI	T060	C0598801
27270538	834	840	scores	T081	C0449820
27270538	868	875	PI-RADS	T170	C4284879
27270538	881	900	diagnostic accuracy	T080	C0598285
27270538	908	915	PI-RADS	T170	C4284879
27270538	916	921	score	T081	C0449820
27270538	942	956	histopathology	T091	C0677043
27270538	960	977	prostate biopsies	T060	C0194804
27270538	1005	1008	PCa	T191	C0376358
27270538	1013	1037	histologically diagnosed	UnknownType	C0679557
27270538	1072	1079	PI-RADS	T170	C4284879
27270538	1080	1085	score	T081	C0449820
27270538	1123	1139	cancer detection	T058	C1516193
27270538	1140	1144	rate	T081	C1521828
27270538	1150	1166	cancer detection	T058	C1516193
27270538	1167	1171	rate	T081	C1521828
27270538	1176	1182	scores	T081	C0449820
27270538	1252	1256	T2WI	T060	C0011923
27270538	1320	1323	DWI	T060	C0598801
27270538	1329	1333	T2WI	T060	C0011923
27270538	1336	1339	DWI	T060	C0598801
27270538	1345	1361	cancer detection	T058	C1516193
27270538	1362	1366	rate	T081	C1521828
27270538	1377	1382	score	T081	C0449820
27270538	1394	1400	scores	T081	C0449820
27270538	1414	1420	scores	T081	C0449820
27270538	1434	1440	scores	T081	C0449820
27270538	1458	1464	scores	T081	C0449820
27270538	1501	1517	cancer detection	T058	C1516193
27270538	1529	1533	T2WI	T060	C0011923
27270538	1543	1546	DWI	T060	C0598801
27270538	1559	1563	T2WI	T060	C0011923
27270538	1566	1569	DWI	T060	C0598801
27270538	1651	1657	scores	T081	C0449820
27270538	1686	1690	T2WI	T060	C0011923
27270538	1693	1696	DWI	T060	C0598801
27270538	1702	1709	PI-RADS	T170	C4284879
27270538	1710	1715	score	T081	C0449820
27270538	1736	1749	PCa detection	T061	C0281186
27270538	1750	1754	rate	T081	C1521828
27270538	1758	1766	patients	T101	C0030705
27270538	1772	1775	PSA	T116,T126,T129	C0138741
27270538	1798	1803	score	T081	C0449820
27270538	1807	1811	T2WI	T060	C0011923
27270538	1814	1817	DWI	T060	C0598801
27270538	1859	1862	PCa	T191	C0376358